EUCTR2006-005703-34-FR进行中（未招募）不适用
Essai de phase II : Folfiri.3 (CPT-11/acide folinique/5-FU) / gemzar en traitement sequentiel des cancers du pancréas métastatiques non pré-traités - firgem
Ageo0 个研究点开始时间: 2007年3月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Pathologically proven pancreatic adenocarcinoma (on primitive or metastatic lesion)
- •- Age between 18 and 75 years
- •- Life expectancy >12 weeks
- •- Performance status OMS < 2
- •- Pain well controlled
- •- Neutrophiles =1500/mm3, platelets = 100000/mm3, Hb = 9g/dl, ASAT and ALAT < 5 UNL, serum bilirubin = 1,5 UNL
- •- Normal renal function test (serum creatinine concentration = 130 mmol/l ou creatine clearance = 60 ml/min)
- •- Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- No prior chemotherapy (except adjuvante chemotherapy with gemcitabine realised more than 12 months before inclusion day)
- •- No prior radiation therapy (except if there is at least one mesurable target outside irradiation area)
- •- Known brain metastasis (no need of systematic CTscan)
- •- Pregnant or feeding woman
- •- Previous carcinoma within the last 5 years (except basal cell carcinoma and in situ carcinoma cervix)
- •- Concomitant antitumoral treatment
- •- Recent (within 30 days prior inclusion) participation in another investigational study
研究者
相似试验
未知
2 期
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal CancerJPRN-jRCT1080220199Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.
已完成
2 期
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal CancerColorectal CancerNCT00284258Taiho Pharmaceutical Co., Ltd.426
未知
2 期
A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancerpreviously untreated pancreatic cancerJPRN-jRCT2080221426Yakult Honsha Co.,Ltd.35
已完成
2 期
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT02028806Yuhong Li40
进行中（未招募）
1 期
Estudio en fase II con dos grupos de FOLFIRI en combinación con la dosis de referencia o escalado de la dosis de cetuximab como tratamiento de primera línea del cáncer colorrectal metastásico con K-Ras de tipo natural: Everest 2 (A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2) - Everest 2cáncer colorrectal metastásico con K Ras de tipo natural (K-Ras wild type metastatic colorectal cancer)MedDRA version: 13Level: LLTClassification code 10052358Term: Cáncer metastásico colorrectalEUCTR2009-009992-36-ESHospital Universitario de Lovaina375